Barclays Downgrades Cellectis to Underweight, Lowers Price Target to $1.3
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsDowngradesPrice Target
Barclays analyst Lukas Shumway downgrades Cellectis (NASDAQ:CLLS) from Overweight to Underweight and lowers the price target from $9 to $1.3.
Barclays analyst Lukas Shumway downgrades Cellectis (NASDAQ:CLLS) from Overweight to Underweight and lowers the price target from $9 to $1.3.